Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D003984:Dibenzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012472:Salivation / Q000187:drug effects; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D013268:Stimulation, Chemical
D014151:Anti-Anxiety Agents; D003984:Dibenzazepines; D010879:Piperazines; D001569:Benzodiazepines; D006220:Haloperidol; D006719:Homovanillic Acid